ପ୍ରୋପାଇହେକ୍ସେଡ୍ରାଇନ

ପ୍ରୋପାଇହେକ୍ସେଡ୍ରାଇନ
Clinical data
Trade names	Benzedrex, Obesin, others
Synonyms	Hexahydro-desoxyephedrine; Hexahydro-methamphetamine; Hydromethamphetamine; Dimethylcyclo-hexaneethanamine; Cycohexyliso-propylmethylamine; Propylhexedrinum
AHFS/Drugs.com	monograph
Pregnancy; category	C;
Routes of; administration	Medical: Intranasal, by mouth; Recreational: By mouth, by injection
Legal status
Legal status	AU: S4 (Prescription only) ; CA: Unscheduled ; US: OTC (nasal inhaler only) ;
Pharmacokinetic data
Onset of action	Within 5 min
Elimination half-life	4 ± 1.5 hours
Duration of action	Up to 2 hrs
Identifiers
	IUPAC name (±)-1-cyclohexyl-N-methylpropan-2-amine;
ECHA InfoCard	100.002.673
Chemical and physical data
Formula	C10H21N
Molar mass	୧୫୫.୨୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N(C(CC1CCCCC1)C)C;
	InChI InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3 ; Key:JCRIVQIOJSSCQD-UHFFFAOYSA-N ;
(verify)

ପ୍ରୋପାଇହେକ୍ସେଡ୍ରାଇନ, ବେପାର ନାମ ବେଞ୍ଜେଡ୍ରେକ୍ସ , ଏକ ଔଷଧ ଯାହା ବନ୍ଦ ନାକ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ନାକରେ ପକାଯାଏ ।^[୧] ଏହାର ପ୍ରଭାବ ୫ ମିନିଟ୍ ମଧ୍ୟରେ ଆରମ୍ଭ ହୁଏ ଏବଂ ୨ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ ରହିପାରେ ।^[୧] ତିନି ଦିନରୁ ଅଧିକ ସମୟ ପାଇଁ ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଜ୍ୱଳନ ଏବଂ ନାକରୁ ତରଳ ପଦାର୍ଥ ବୋହିଯାଏ ।^[୧] ଅନ୍ୟାନ୍ୟ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ମୁଣ୍ଡବିନ୍ଧା, ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ ସାଇକୋସିସ୍ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ । ^[୧] ଏହା ଆମ୍ଫେଟାମିନ ପରି ଛୋଟ ଧମନୀକୁ ସଙ୍କୁଚିତ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୧]

୧୯୪୯ ମସିହାରେ ପ୍ରୋପାଇହେକ୍ସେଡ୍ରାଇନ ବ୍ୟବସାୟିକ ବ୍ୟବହାରରେ ଆସିଥିଲା ।^[୩] ଏହା କାଉଣ୍ଟର ଉପରେ ଉପଲବ୍ଧ ।^[୧] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ଏକ ବିତରଣ ଉପକରଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧୩ ଡଲାର ଥିଲା ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଏକ ନିୟନ୍ତ୍ରିତ ପଦାର୍ଥ ନୁହେଁ ।^[୧] ଏହା ଓଜନ ହ୍ରାସ ପାଇଁ ମଧ୍ୟ ବ୍ୟବହୃତ ହୋଇଛି ଏବଂ ନିଶାଗ୍ରସ୍ତ ହେବାକୁ ଚେଷ୍ଟା କରୁଥିବା ଲୋକମାନଙ୍କଦ୍ୱାରା ଅପବ୍ୟବହାର କରାଯାଇଛି ।ଆ^[୫] ^[୬] ^[୭]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ ^୧.୧୦ "Propylhexedrine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 29 October 2021.
↑ "DailyMed - BENZEDREX 09-19-2014- propylhexedrine inhalant". dailymed.nlm.nih.gov. Archived from the original on 26 March 2021. Retrieved 29 October 2021.
↑ MD, Steven B. Karch; Drummer, Olaf (11 November 2015). Karch's Pathology of Drug Abuse (in ଇଂରାଜୀ). CRC Press. p. 1734. ISBN 978-1-4987-6650-0. Archived from the original on 30 October 2021. Retrieved 29 October 2021.
↑ "Benzedrex Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2021.
↑ Dart, Richard C. (2004). Medical Toxicology (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. 1073. ISBN 978-0-7817-2845-4. Archived from the original on 30 October 2021. Retrieved 29 October 2021.
↑ Docherty JR (June 2008). "Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)". British Journal of Pharmacology. 154 (3): 606–22. doi:10.1038/bjp.2008.124. PMC 2439527. PMID 18500382.
↑ Ries, Richard K.; Miller, Shannon C.; Fiellin, David A. (2009). Principles of Addiction Medicine (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. 138. ISBN 978-0-7817-7477-2. Archived from the original on 30 October 2021. Retrieved 29 October 2021.

[AHFS2021-1] ୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ ^୧.୧୦ "Propylhexedrine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 29 October 2021.

[2] "DailyMed - BENZEDREX 09-19-2014- propylhexedrine inhalant". dailymed.nlm.nih.gov. Archived from the original on 26 March 2021. Retrieved 29 October 2021.

[3] MD, Steven B. Karch; Drummer, Olaf (11 November 2015). Karch's Pathology of Drug Abuse (in ଇଂରାଜୀ). CRC Press. p. 1734. ISBN 978-1-4987-6650-0. Archived from the original on 30 October 2021. Retrieved 29 October 2021.

[4] "Benzedrex Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2021.

[5] Dart, Richard C. (2004). Medical Toxicology (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. 1073. ISBN 978-0-7817-2845-4. Archived from the original on 30 October 2021. Retrieved 29 October 2021.

[6] Docherty JR (June 2008). "Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)". British Journal of Pharmacology. 154 (3): 606–22. doi:10.1038/bjp.2008.124. PMC 2439527. PMID 18500382.

[Ries2009-7] Ries, Richard K.; Miller, Shannon C.; Fiellin, David A. (2009). Principles of Addiction Medicine (in ଇଂରାଜୀ). Lippincott Williams & Wilkins. p. 138. ISBN 978-0-7817-7477-2. Archived from the original on 30 October 2021. Retrieved 29 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]